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1  | BACKGROUND
The global hepatitis C virus (HCV) epidemic stimulated the World 
Health Organization (WHO) to develop viral hepatitis elimination 
targets in 2016.1 An estimated 71 million people worldwide were 
infected by HCV in 2015.2 Thus, the WHO set the target of a 90% 
reduction in new infections and a 65% reduction in viral hepatitis-re-
lated mortality by 2030 as compared to 2015. These are ambitious 
but feasible goals, since we have ample tools at hand to curtail the 
current HCV epidemic. The diagnosis of active HCV can be readily 
made, by means of sample analysis in a central facility or through 
point-of-care testing. Direct-acting antivirals (DAAs) cure the 
infection in ≥95% of cases.3 Pangenotypic DAAs can be used in all 
patients with only a few barriers such as potential drug-drug inter-
actions or presence of (decompensated) cirrhosis.4,5 Most countries 
have assessed their specific HCV population and the availability of 
tools in their countries and subsequently developed national hepati-
tis plans in line with the WHO elimination targets.6
HCV elimination according to the WHO goals can be achieved 
in various ways, which ideally should be incorporated in a multi-
faceted approach. We can focus on prevention, by developing a 
vaccine or by increasing awareness and educating groups at risk 
of transmission of the virus. Secondly, we can develop or augment 
existing screening strategies, in order to diagnose more patients. 
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Since the advent of direct-acting antivirals, elimination of hepatitis C viral (HCV) in-
fections seems within reach. However, studies on the HCV cascade of care show 
suboptimal progression through each step for all patient groups. Loss to follow-up 
(LTFU) is a major issue and is a barrier to HCV elimination. This review summarizes 
the scale of the LTFU problem and proposes a micro-elimination approach. Retrieving 
LTFU patients and re-engaging them with care again has shown to be feasible in 
the Netherlands. Micro-elimination through retrieval can contribute to reaching the 
World Health Organization's viral hepatitis elimination targets by 2030.
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Lastly, we can treat as many infected patients as possible. Since the 
development of highly effective and tolerable DAAs, HCV elimina-
tion projects have primarily focused on prevention and screening, 
since treatment was not seen as a problem anymore. However, en-
suring treatment for all diagnosed patients remains a problem to 
this day.
Loss to follow-up (LTFU) prevents patients from receiving the 
care they need to be cured of their infection. The extent of this 
problem remains unclear, especially in the DAA era. In order to grasp 
the scope of the LTFU problem, one needs to understand the HCV 
care cascade and how patients move through its phases. This review 
aims to assess published literature on LTFU in the HCV cascade of 
care during the DAA era and will provide an overview of issues and 
possible solutions.
2  | CONCEPT OF LOSS TO FOLLOW-UP
Different definitions for LTFU are used in the literature, since patients 
become lost to follow-up for various reasons. For example, they may 
have moved house, emigrated, died or been imprisoned. Many times, 
the reason for LTFU cannot be ascertained as contact with the patient 
cannot be established. Retrospective observational studies often do 
not provide a specific definition or use nonattendance to any appoint-
ment as a definition.Suppl file 1-11 Some of these studies mention death 
separately and do not include this as a reason for LTFU.Suppl file 12-17 
Other studies that reviewed ever-diagnosed patients defined LTFU as 
patients who never or not recently had an appointment with an HCV 
specialist.Suppl file 18,19 Interventional studies aiming to improve the 
cascade of care also do not give a definition or define LTFU as nonat-
tendance anywhere in the care cascade,Suppl file 20-49 often separating 
death from the LTFU group.Suppl file 50-58 There are some studies that 
include multiple LTFU definitions and report data on all of them, such 
as nonattendance, nonresponse to invitation, moved, incarcerated, no 
insurance and comorbidities.Suppl file 59-62
There may be a lesson to be learned on defining LTFU from stud-
ies in other fields of medicine. Previously mentioned HCV studies 
did not take time into account when defining LTFU. Prospective 
studies defined LTFU as nonattendance at the end of their study 
period, which varied greatly among studies. Retrospective studies 
defined LTFU as nonattendance since their last visit up to study 
initiation. HIV studies have investigated LTFU extensively and 
showed that the way you define LTFU greatly influences your LTFU 
outcomes.7 In addition, these studies have demonstrated differ-
ent ways to determine the ideal timeframe to classify someone as 
LTFU, that is x days after last clinic visit.8,9 When different studies 
use different definitions, it is virtually impossible to compare care 
cascades and combine results. However, since this is the case for 
the HCV studies assessed in this review, we chose a pragmatic ap-
proach that suits the illustrative purpose of this review. We define 
LTFU as nonattendance to any appointment in the care cascade 
at any time since their last visit. Patients who had died were not 
included in the definition of LTFU.
3  | THE HC V C ARE C A SC ADE
In order to grasp the magnitude of the LTFU problem in chronic 
HCV patients, we must first understand the HCV care cascade. 
Reviewing published literature on this subject shows that defi-
nitions of the care cascade vary with each paper. However, ef-
forts to come up with an unambiguous description of the HCV 
care cascade have been made. In 2018, the WHO established a 
monitoring framework that includes 10 core indicators address-
ing prevention, diagnosis, treatment and mortality.10 The WHO 
states that four of the 10 core indicators should be used for cas-
cade of care reporting: the number of patients infected, diag-
nosed, treated and cured.11 Recently, a study group comprised of 
clinical, epidemiological and public health experts from Australia, 
Europe and North America have proposed a clarified and slightly 
extended care continuum.12 Their Consensus HCV Cascade of 
Care (CHCoC) is based on the WHO indicators, a review of pub-
lished literature on HCV care continuums and on methodologi-
cal issues in HIV cascade of care monitoring. It can be divided 
into four key steps (the four WHO indicators) and three supple-
mentary steps: (a) estimated HCV prevalence; (b) diagnosed with 
F I G U R E  1   Hepatitis C care cascade. Step 1: HCV prevalence; step 2: diagnosed with chronic HCV; step 3: linked to care; step 4: liver 
disease assessed; step 5: started on treatment; step 6: achieved SVR; step 7: accessed chronic post-SVR care. Figure freely adapted with 
permission from Safreed-Harmon et al.12 HCV, hepatitis C virus; LTFU, lost to follow-up; SVR, sustained virological response
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chronic HCV; (c) linked to HCV care; (d) liver disease assessed; 
(e) started on treatment in (year); (f) achieved sustained virologi-
cal response (SVR) in (year); and (g) accessed chronic post-SVR 
care. The authors provided pragmatic definitions for the four 
key steps, which stakeholders can use to report on elimination 
progress. Understandably, by increasing the number of steps in 
the care cascade, the chances of being lost from care also in-
crease. LTFU is seen as a major problem, because it remains un-
sure whether the patient is cured or not. Liver disease in these 
patients may progress, and they may even contribute to HCV 
transmission if they still exhibit certain risk behaviour. When 
reviewing the literature published on HCV care cascades in the 
DAA era and their LTFU rates, we used the CHCoC to report our 
findings (see Figure 1). And overview and characteristics of the 
included studies in this review can be found in Table 1.
4  | LTFU DURING DIAGNOSTIC 
A SSESSMENT (CHCOC STEP 2)
The first step in diagnosing chronic HCV is the determination of 
presence of HCV antibodies. However, the key step in confirming 
the diagnosis of chronic HCV is determining HCV RNA (or HCV core 
antigen when RNA assays are not available or not affordable).13 In 
many countries, HCV RNA is not tested automatically after receiving 
a positive antibody test result. This two-step diagnosis provides the 
first opportunity for patients to become LTFU. Two retrospective, 
observational studies have shown that approximately 72% of their 
anti-HCV-positive populations were tested for HCV RNA.Suppl file 1,2 
This percentage is generally higher in interventional studies aiming 
to improve the cascade of care, often done in community-based set-
tings: 67%-100% (median 90%).Suppl file 20-23,50-52,59 However, some 
studies have shown that only 7%Suppl file 18 or 18%Suppl file 24 of anti-
HCV-positive people receive confirmatory testing. Reasons for this 
vary and are often unreported, but might be due to LTFU. One study 
confirmed that 32% of anti-HCV-positive people were LTFU before 
receiving an RNA test.Suppl file 50 Reflex testing, where the laboratory 
automatically tests for HCV RNA or HCV core antigen when the an-
tibody test proves to be positive, improves this step in the cascade 
of care.Suppl file 27
5  | LTFU BEFORE LINK AGE TO HC V C ARE 
(CHCOC STEP 3)
When someone has tested positive for HCV RNA, referral to an HCV 
specialist for further evaluation should follow. However, attendance 
to this follow-up visit is only reported in 27%-91% (median 68%) of 
cases.Suppl file 1,18-22,25-28,52,59,60 People who inject(ed) drugs (PWID), 
a well-known hard to reach population, attend in 36%-65% of cases 
(median 50%).Suppl file 29-32 In HIV/HCV-coinfected patients, attend-
ance seems to be higher with 25%-95% (median 90%).Suppl file 8,11,47,49 
Generally speaking, attendance is higher for those under decentralized 
care. Reasons for absence are difficult to assess; however, some stud-
ies confirm LTFU in 26%-100% (median 84%) of absentees.Suppl file 
22,27,32,52,59,60
6  | LTFU DURING LIVER DISE A SE 
A SSESSMENT (CHCOC STEP 4)
Several diagnostic procedures are available to grade and stage 
liver disease. Where liver biopsy was standard of care in the past, 
nowadays noninvasive methods are largely preferred. Liver fi-
brosis may be quantified by using serological panels, such as the 
widely used FIB-4 (using the patient's age, platelet count, AST and 
ALT levels) or APRI score (using AST levels, the AST upper limit 
of normal and platelet count), or by using transient elastography. 
Almost all studies in the DAA era employ noninvasive ways to 
assess liver disease severity. When looking at people who have 
attended their first visit after being diagnosed or referred, fibro-
sis was assessed with the APRI scoreSuppl file 2,24,33 in 52%-99% 
(median 87%) and with FibroScanSuppl file 9,12,22,25,27,30,34,35,40,41,5
0,53 in 59%-100% (median 79%). Studies which used other non-
invasive measures or did not report which measures were used, 
reported assessment in 48%-95% (median 88%) of attendees.Suppl 
file 20,21,25,26,36 LTFU may contribute to this suboptimal assessment 
rate and should be addressed.
7  | LTFU BEFORE INITIATING TRE ATMENT 
(CHCOC STEP 5)
Even in the era of highly effective DAAs, treatment initiation rates 
are low. LTFU proves to be a large contributor to this problem. 
Retrospective studies have shown that only 12%-77% (median 
29%) of patients diagnosed or engaged in care during the DAA era 
initiated treatment after being diagnosed with chronic HCV.Suppl 
file 1-5,13,34 Interventional studies aimed to improve the care cas-
cade show that this rate can increase to 16%-100% (median 
73%).Suppl file 18-28,33,35-39,50-53,59-62 Studies in the HIV field show 
similar results, with 36%-91% (median 90%) initiating treatment 
in retrospective studiesSuppl file 9-11 and 25%-100% (median 80%) 
in interventional studies.Suppl file 47-49 However, the treatment rate 
remains suboptimal in PWID with only 20%-90% (median 53%) 
initiating treatment.Suppl file 29-32,40,41 Generally, treatment initia-
tion rates are higher in decentralized settings, both in PWID and 
non-PWID populations. Reasons for poor treatment initiation 
rates vary. Unfortunately, many countries still experience restric-
tions in who can and cannot be treated with DAAs.14,15 This prob-
lem may especially apply to studies from the first stages of the 
DAA era.16 Other reasons for poor treatment initiation rates may 
be comorbidities or perceived lack of compliance. However, LTFU 
contributes to a large extent to these poor rates. Studies showed 
that LTFU is the reason for nontreatment in 0%-67% (median 
33%) of cases.Suppl file 3,5,13,19,25-27,32,40,41,53,61,62









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1280  |     van DIJK et al.
8  | LTFU DURING OR AF TER TRE ATMENT 
(CHCOC STEP 6)
As we know from registration trials, DAAs are highly effective. 
Real-world studies yield similar results. However, LTFU influ-
ences result in real-world studies significantly more. Recently, 
Darvishian et al showed that LTFU exceeded viral failure in their 
real-world study, impeding the cascade of care. Studies show that 
0%-11% (median 3.4%) of patients become LTFU during thera-
pySuppl file 6,13,26,28,33,37,42,43,50-53,55-57,62 and that 0%-25% (median 
4.9%) become LTFU after therapy completion, with missing SVR 
values.Suppl file 6,13,26,28,33,37,42,43,51-53,55,56,60,62 PWID show simi-
lar results with 0.7%-5.6% (median 2.5%) becoming LTFU during 
treatmentSuppl file 7,40,44,54,58 and 2.5%-28% (median 7.1%) after.Suppl 
file 7,31,40,41,44,54,58
Many studies report intention-to-treat SVR percentages, defined 
as the proportion of patients who reached SVR out of the number 
of patients that initiated DAA therapy (see Figure 2). In studies in-
cluding mixed populations, ITT SVR varies from 22% to 98% (median 
83%).Suppl file 1,2,4-6,12,13,16,18,21-23,25-28,33,35-37,39, 42,43,50-53,55-57,60-62 In 
studies focusing on PWID populations, ITT SVR ranges from 80% to 
92% (median 85%).Suppl file 7,29-32,40,41,44,54,58 Lastly, in studies focus-
ing on HIV/HCV-coinfected populations, ITT SVR ranges from 80% 
to 96% (median 91%).Suppl file 8-11,15,47-49
9  | LTFU AF TER SVR (CHCOC STEP 7)
Guidelines suggest that people with advanced fibrosis (METAVIR 
score F3) or cirrhosis (F4) who reached SVR should be subjected to 
surveillance for hepatocellular carcinoma (HCC) every six months 
by means of ultrasound.13,17 Furthermore, cirrhotic patients with 
varices present at pre-treatment endoscopy should be surveyed for 
oesophageal varices.13,17 Unfortunately, data on how many cured 
patients actually receive such surveillance are lacking. Most studies 
stop reporting on the care cascade at the moment SVR is reached. 
A recent review showed that less than 30% of cirrhotic patients are 
included in surveillance programmes, independent from aetiology.18 
More studies on the surveillance adherence among cured HCV pa-
tients with an indication for surveillance are needed.
10  | FAC TORS A SSOCIATED WITH LTFU
Younger age (~45 and younger),Suppl file 12,46,58,60 treatment in 
hospital,Suppl file 18 a history of homelessness,Suppl file 19,54 mental 
illnessSuppl file 15,45 and insurance typeSuppl file 26,60 were some of the 
most common factors associated with LTFU. Factors associated 
with retention in care were older age (~60 and older)Suppl file 14,16 
and HIV coinfection.Suppl file 14,46 However, one study with HIV co-
infected patients showed that detectable HIV viral load was actu-
ally associated with LTFU,Suppl file 45 possibly reflecting suboptimal 
retention in HIV care. Studies on the HCV care cascade in people 
living with HIV confirm relatively good retention in care, espe-
cially after starting treatment.Suppl file 8-11,15,17,45,47-49 The last fac-
tors that were often associated with LTFU are linked to injecting 
drug use. Past,Suppl file 14 recentSuppl file 7,14 or ongoing drug useSuppl 
file 15,19,45 was mentioned in several studies as being associated 
with LTFU. Receiving opioid substitution therapy in one centre 
and DAA treatment in another was also associated with LTFU.Suppl 
file 7,56
11  | MICRO -ELIMINATION OF LTFU 
PATIENTS THROUGH RETRIE VAL
LTFU occurs in all steps of the care cascade and may severely im-
pact HCV care and opportunities for cure. It is reasonable to as-
sume that data from the interferon era on LTFU are worse, due 
to the fact that fewer patients had an indication for treatment, 
more patients refused treatment, fewer patients finished the ill-
tolerated treatment and only a limited number of patients achieved 
cure, compared to the DAA era. This hypothesis was confirmed in a 
recent study by Aleman et al19 The authors included HCV patients 
from their national register diagnosed between 2001 and 2011 
and alive in 2013, and found that an impressive 61% was LTFU. A 
study from Belgium using a similar approach showed that PWID 
and patients who never received HCV treatment had a higher 
risk of becoming LTFU (OR 2.2 for both).20 This provides us with 
an opportunity as the LTFU HCV population may be an excellent 
candidate for micro-elimination, the process of eliminating HCV in 
subpopulations.21 Micro-elimination is the favoured approach in 
many countries, especially in those with a relatively low national 
prevalence, but higher prevalence in specific subpopulations. 
Lazarus et al have recently described which subpopulations should 
be considered for micro-elimination, such as aboriginal and indig-
enous communities, HIV/HCV-coinfected people, migrants from 
high-prevalence countries, people who inject drugs, people with 
inherited blood disorders and prisoners.22 We propose that LTFU 
patients should be added to this list. As indicated, LTFU is a sub-
stantial problem across the entire care cascade. Because this HCV 
population has already been identified, it is obvious that retrieval 
of these patients can be considered ‘low-hanging fruit’.
12  | RETRIE VAL IN THE NETHERL ANDS: 
THE CELINE PROJEC T
Several regional projects have been executed in the Netherlands fo-
cused on the LTFU population. We found that up to 14% of our HCV 
population diagnosed in the previous 15 years was LTFU before being 
cured and eligible for retrieval.23-25 Based on best practices from these 
projects, a nationwide approach was developed.26,27 The hepatitis C 
Elimination in the Netherlands (CELINE) project aims to retrieve LTFU 
chronic HCV patients and re-engage them with care. The protocol 
is described in detail elsewhere.27 In short, we identify diagnosed 
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patients based on laboratory data, which we combine with information 
from their medical records. Patients who were still HCV-positive when 
they left care are classified as eligible for retrieval if they are alive and 
currently residing in the Netherlands. They are subsequently invited by 
letter to an outpatient clinic of their choice after their current address 
is verified through municipality records or general practitioners. Data 
will be collected on patient and disease characteristics of patients who 
sign informed consent.
What we have learned since the start of CELINE in 2018 is that 
retrieval is feasible when conducted by a dedicated team. The project 
gives great insight into our care cascade and gives vital information for 
our hepatitis elimination plan. The nationwide approach ensures that 
retrieval is done to the same standards in each participating centre. 
Identification of LTFU patients and ensuring they adhere to their clinic 
appointments are the most time-consuming. This is why we advise 
that a dedicated team, rather than individual clinicians, should execute 
these tasks.
13  | INCLUDE RETRIE VAL IN STANDARD 
C ARE
Ideally, micro-elimination through retrieval should become standard 
of care. This concept is not (yet) mentioned in any guidelines or elimi-
nation plans, but deserves attention since it can contribute to HCV 
elimination. Retrieval could be done yearly, to reduce workload, and 
requires close collaboration between microbiologists/virologists, 
infectious disease specialists, hepatologists, hepatitis nurses and 
other parties such as addiction care medicine, prisons, public health 
institutes and/or general practitioners. Each centre could form a 
multidisciplinary team led by a dedicated retrieval coordinator, for 
example a hepatitis nurse. This coordinator could check the care 
cascade of all people who had a positive HCV test result in the previ-
ous year. The team could subsequently develop a multidisciplinary 
approach to retrieve LTFU patients. Patient-centred care is key in 
retrieving LTFU patients.
14  | ENSURING RETAINMENT IN C ARE
Efforts should be made to retain LTFU and non-LTFU patients in 
care. The cascade of care should be simplified as much as possible, 
as is stated in the call to action from the American Association for 
the Study of Liver Diseases (AASLD), the European Association 
for the Study of the Liver (EASL), the Asian Pacific Association for 
the Study of the Liver (APASL) and the Latin American Association 
for the Study of the Liver (ALEH), in partnership with the Clinton 
Health Access Initiative (CHAI).28 Pre-treatment diagnostic as-
sessment should be performed in one appointment. Treatment 
should be offered to all RNA-positive patients. Patients should be 
F I G U R E  2   Intention-to-treat sustained 
virological response percentages in 
studies included in this review in mixed 
populations, people who inject(ed) drugs 
and HIV/HCV-coinfected patients. Each 
line represents one study or one study 
group. The corresponding number refers 
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treated using pangenotypic regimens, making genotyping before-
hand obsolete. Monitoring during treatment should be kept to a 
minimum. Care should be decentralized and/or integrated within 
other disease programmes as much as possible. Task-sharing be-
tween HCV specialists and other healthcare workers should be 
encouraged. Patients should be educated about the risk of re-in-
fection. Lastly, some patients should be retained in post-SVR care, 
according to guidelines. This includes patients with a continuing 
risk of developing HCC, such as patients with advanced fibrosis 
(METAVIR score F3) or cirrhosis (F4) or patients with other risk 
factors such as excessive alcohol drinking, obesity and/or type 
2 diabetes, but also patients with persisting abnormal liver tests 
that could indicate other causes of liver disease. These efforts can 
contribute to retainment in care and can therefore contribute to 
HCV elimination.
15  | CONCLUSION
LTFU is a problem in each step in the HCV care cascade, even in 
the current era where highly effective treatments are available and 
where it has been possible to simplify the cascade of care. HCV 
can be micro-eliminated in the LTFU population through retrieval. 
We present an example of nationwide retrieval in the Netherlands, 
which shows retrieval is feasible and can contribute to HCV elimi-
nation. We propose that micro-elimination through retrieval be-
comes standard of care on the road to viral hepatitis elimination. 
Furthermore, efforts to retain patients in care should be imple-
mented in daily clinical practice.
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